Universität zu Köln

Popp, Felix C., Popp, Marie Christine, Zhao, Yue, Betzler, Christopher, Kropf, Siegfried, Garlipp, Benjamin, Benckert, Christoph, Kalinski, Thomas, Lippert, Hans and Bruns, Christiane J. (2017). Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease. BMC Cancer, 17. LONDON: BIOMED CENTRAL LTD. ISSN 1471-2407

Full text not available from this repository.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies today with an urgent need for novel therapeutic strategies. Biomarker analysis helps to better understand tumor biology and might emerge as a tool to develop personalized therapies. The aim of the study is to investigate four promising biomarkers to predict the clinical course and particularly the pattern of tumor recurrence after surgical resection. Design: Patients undergoing surgery for PDAC can be enrolled into the PANCALYZE trial. Biomarker expression of CXCR4, SMAD4, SOX9 and IFIT3 will be prospectively assessed by immunohistochemistry and verified by rt.-PCR from tumor and adjacent healthy pancreatic tissue of surgical specimen. Immunohistochemistry expression pattern of all four biomarkers will be combined into a single score. Beginning with the hospital stay clinical data from enrolled patients will be collected and followed. Different adjuvant chemotherapy protocols will be used to create subgroups. The combined biomarker expression score will be correlated with the further clinical course of the patients to test the hypothesis if CXCR4 positive, SMAD4 negative, SOX9 positive, IFIT3 positive tumors will predominantly develop metastatic spread. Discussion: Pancreatic cancer is associated with different patterns of progression requiring personalized therapeutic strategies. Biomarker expression analysis might be a tool to predict the pattern of tumor recurrence and discriminate patients that develop systemic metastatic disease from those with tumors that rather develop local recurrence over time. This data might lead to personalized adjuvant treatment decisions as patients with tumors that stay localized might benefit from adjuvant local therapies like radiochemotherapy as compared to those with systemic recurrence who would benefit exclusively from chemotherapy. Moreover, the pattern of propagation might be a predefined characteristic of pancreatic cancer determined by the genetic signature of the tumor. In the future, biomarker expression analysis could be performed on tumor biopsies to develop personalized therapeutic pathways right after diagnosis of cancer.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Popp, Felix C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Popp, Marie Christine UNSPECIFIED UNSPECIFIED UNSPECIFIED Zhao, Yue UNSPECIFIED UNSPECIFIED UNSPECIFIED Betzler, Christopher UNSPECIFIED UNSPECIFIED UNSPECIFIED Kropf, Siegfried UNSPECIFIED UNSPECIFIED UNSPECIFIED Garlipp, Benjamin UNSPECIFIED UNSPECIFIED UNSPECIFIED Benckert, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Kalinski, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Lippert, Hans UNSPECIFIED UNSPECIFIED UNSPECIFIED Bruns, Christiane J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-236254
DOI:	10.1186/s12885-017-3186-8
Journal or Publication Title:	BMC Cancer
Volume:	17
Date:	2017
Publisher:	BIOMED CENTRAL LTD
Place of Publication:	LONDON
ISSN:	1471-2407
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHEMOKINE RECEPTOR CXCR4; DUCTAL ADENOCARCINOMA; CANCER METASTASIS; ROC CURVES; EXPRESSION; CHEMORADIATION; CHEMOTHERAPY; INVOLVEMENT; PROGRESSION; NEOPLASMS Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/23625